Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression signatures after immunisation with Boostrix - alum adsorbed tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (BIOVACSAFE protocol 305D2)

ABSTRACT: The time course of whole blood gene expression was determined in healthy adult human participants who were randomised to receive either a single intramuscular immunisation with Boostrix vaccine (characteristics: treatment = BOOSTRIX) or equivalent volume saline control (characteristics: treatment = PLACEBOD2). Participants are identified who reported having had an immunisation with Boostrix within the past 5 years (characteristics: recent boostrix = 1).

ORGANISM(S): Homo sapiens

PROVIDER: GSE124842 | GEO | 2022/01/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression signatures after immunisation with Boostrix - alum adsorbed tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (BIOVACSAFE protocol 305D2)

Project description:Gene expression signatures after immunisation with Boostrix - alum adsorbed tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (BIOVACSAFE protocol 305D2)

| PRJNA514018 | ENA

Gene expression signatures after immunisation with MF59C adjuvanted trivalent inactivated influenza vaccine for season 2014-2015 Northern hemisphere (BIOVACSAFE protocol 305D)

Project description:The time course of whole blood gene expression was determined in healthy adult participants who were randomised to receive either a single intramuscular immunisation with MF59C adjuvanted influenza vaccine (FLUADD) or equivalent volume saline control (PLACEBOD).

2019-12-31 | GSE124689 | GEO

Gene expression signatures after immunisation with a range of live, inactivated and adjuvanted vaccines (BIOVACSAFE protocols 305A, 305B and 305C)

Project description:The time course of whole blood gene expression was determined in healthy adult participants residing in an inpatient unit (CRC, University of Surrey, UK) to minimise background environmental variation, who were randomised into three protocols (305A, 305B and 305C) with study groups within each protocol (n = 20/21) receiving a single immunisation with a licensed vaccine or saline placebo control.

2019-01-06 | GSE124533 | GEO

Gene expression signatures after immunisation with an HIV-1 recombinant Vesicular Stomatitis Virus (VSV) vaccine following three priming doses of IL-12 pDNA enhanced HIV-1 multi-antigen pDNA vaccine (BIOVACSAFE protocol HVTN087)

Project description:The time course of whole blood gene expression was measured after the fourth immunisation at month 6 in participants who had been randomised into vaccine or placebo group 1 of the clinical protocol HVTN087 - A phase 1 trial to evaluate the safety, tolerability, and immunogenicity of an IL-12 pDNA enhanced HIV-1 multi-antigen pDNA vaccine delivered intramuscularly with electroporation, with an HIV-1 rVSV vaccine boost, in healthy HIV-uninfected adult participants (NCT01578889).

2022-01-12 | GSE125019 | GEO